XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.24.3

Equity | 9 Months Ended
--- | ---
Sep. 30, 2024
Equity [Abstract] |
Equity | Equity
| Three Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at July 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 4,745 |  | — |  | — |  | — |  | — |  | 4,745 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (16) |  | — |  | — |  | — |  | (16) |
Cash dividends declared on common stock ($0.73 per share) | — |  | — |  | — |  | (1,861) |  | — |  | — |  | — |  | — |  | (1,861) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 4 |  | (466) |  | — |  | (466) |
Share-based compensation plans and other | — |  | — |  | 139 |  | — |  | — |  | — |  | 12 |  | — |  | 151 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 5 |  | 5 |
Balance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |
Balance at July 1, 2024 | 3,577 |  | $ | 1,788 |  | $ | 44,362 |  | $ | 60,187 |  | $ | (5,361) |  | 1,041 |  | $ | (57,394) |  | $ | 66 |  | $ | 43,648 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 3,157 |  | — |  | — |  | — |  | — |  | 3,157 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (10) |  | — |  | — |  | — |  | (10) |
Cash dividends declared on common stock ($0.77 per share) | — |  | — |  | — |  | (1,960) |  | — |  | — |  | — |  | — |  | (1,960) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 4 |  | (444) |  | — |  | (444) |
Share-based compensation plans and other | — |  | — |  | 168 |  | — |  | — |  | — |  | 9 |  | — |  | 177 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 4 |  | 4 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (12) |  | (12) |
Balance at September 30, 2024 | 3,577 |  | $ | 1,788 |  | $ | 44,530 |  | $ | 61,384 |  | $ | (5,371) |  | 1,045 |  | $ | (57,829) |  | $ | 58 |  | $ | 44,560 |
| Nine Months Ended September 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at January 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 1,591 |  | — |  | — |  | — |  | — |  | 1,591 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (148) |  | — |  | — |  | — |  | (148) |
Cash dividends declared on common stock ($2.19 per share) | — |  | — |  | — |  | (5,590) |  | — |  | — |  | — |  | — |  | (5,590) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 9 |  | (953) |  | — |  | (953) |
Share-based compensation plans and other | — |  | — |  | (21) |  | — |  | — |  | (6) |  | 376 |  | — |  | 355 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 12 |  | 12 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (25) |  | (25) |
Balance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |
Balance at January 1, 2024 | 3,577 |  | $ | 1,788 |  | $ | 44,509 |  | $ | 53,895 |  | $ | (5,161) |  | 1,045 |  | $ | (57,450) |  | $ | 54 |  | $ | 37,635 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 13,374 |  | — |  | — |  | — |  | — |  | 13,374 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (210) |  | — |  | — |  | — |  | (210) |
Cash dividends declared on common stock ($2.31 per share) | — |  | — |  | — |  | (5,885) |  | — |  | — |  | — |  | — |  | (5,885) |
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 7 |  | (817) |  | — |  | (817) |
Share-based compensation plans and other | — |  | — |  | 21 |  | — |  | — |  | (7) |  | 438 |  | 1 |  | 460 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 15 |  | 15 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (12) |  | (12) |
Balance at September 30, 2024 | 3,577 |  | $ | 1,788 |  | $ | 44,530 |  | $ | 61,384 |  | $ | (5,371) |  | 1,045 |  | $ | (57,829) |  | $ | 58 |  | $ | 44,560 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration